Clemens Scherzer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio J, et al. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat Neurosci. 2018;21:1482-1492 pubmed publisher
    ..This study shows that enhancers in dopamine neurons link genetic variation to neuropsychiatric traits. ..
  2. Locascio J, Eberly S, Liao Z, Liu G, Hoesing A, Duong K, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015;138:2659-71 pubmed publisher
    ..Moreover, the three independent biobank cohorts provide a generally useful platform for rapidly validating any biological marker of this common disease. ..
  3. Scherzer C, Eklund A, Morse L, Liao Z, Locascio J, Fefer D, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007;104:955-60 pubmed
    ..59 +/- 0.05) than in controls (0.96 +/- 0.09) (P = 0.002) in two independent populations. Thus, gene expression signals measured in blood can facilitate the development of biomarkers for PD. ..
  4. Scherzer C, Grass J, Liao Z, Pepivani I, Zheng B, Eklund A, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008;105:10907-12 pubmed publisher
    ..This critical link between GATA factors and SNCA may enable therapies designed to lower alpha-synuclein production. ..
  5. Liu G, Locascio J, Corvol J, Boot B, Liao Z, Page K, et al. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017;16:620-629 pubmed publisher
    ..This model could improve trials of cognitive interventions and inform on prognosis. National Institutes of Health, US Department of Defense. ..
  6. Mittal S, Bjørnevik K, Im D, Flierl A, Dong X, Locascio J, et al. ?2-Adrenoreceptor is a regulator of the ?-synuclein gene driving risk of Parkinson's disease. Science. 2017;357:891-898 pubmed publisher
    ..2AR activation protected model mice and patient-derived cells. Thus, ?2AR is linked to transcription of ?-synuclein and risk of PD in a ligand-specific fashion and constitutes a potential target for therapies. ..